Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

RAPIVAB

PERAMIVIR

Standard Dose
200MG/20ML (10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview RAPIVAB is listed in Drugs@FDA under application 206426 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PERAMIVIR Form and strength SOLUTION;INTRAVENOUS - 200MG/20ML (10MG/ML) Sponsor BIOCRYST Submission history Latest submission status date: 2024-06-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview RAPIVAB is listed in Drugs@FDA under application 206426 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PERAMIVIR Form and strength SOLUTION;INTRAVENOUS - 200MG/20ML (10MG/ML) Sponsor BIOCRYST Submission history Latest submission status date: 2024-06-13 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.